A bioconjugation technology that enzymatically links bacterial polysaccharide antigens to engineered carrier proteins within a single E. coli cell for vaccine development.

Vaccines developed using the bioconjugation platform targeting bacterial pathogens such as Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae.